智通财经APP讯，上海医药(02607)发布公告，近日，上海医药集团股份有限公司(以下简称“上海医药”或“公司”)下属上海禾丰制药有限公司(以下简称“上药禾丰”)的重酒石酸去甲肾上腺素注射液(规格：1ml:2mg;以下简称“该药品”)收到国家药品监督管理局(以下简称“国家药监局”)颁发的《药品补充申请批准通知书》(通知书编号： 2025B02097)，该药品通过仿制药一致性评价。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.